Organon (OGN) Non-Current Assets (2020 - 2026)
Organon (OGN) recorded quarterly Non-Current Assets of $8.1 billion in Q1 2026, down 5.3% quarter-over-quarter from $8.5 billion in Q4 2025, and down 8.21% on a YoY basis from $8.8 billion in Q1 2025.
Organon (OGN) Non-Current Assets (2020 - 2026) Analysis & Trends
Organon's Non-Current Assets history runs 7 years deep, the most recent figure standing at $8.1 billion for Q1 2026.
- In Q1 2026, Non-Current Assets fell 8.21% year-over-year to $8.1 billion; the TTM figure through Mar 2026 stood at $34.3 billion (up 3.42% YoY), while the FY2025 annual figure was $8.5 billion, down 2.72% from the prior year.
- Non-Current Assets was $8.1 billion for Q1 2026 at Organon, down from $8.5 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $8.9 billion in Q2 2025 to a low of $6.8 billion in Q2 2022.
- Historically, Non-Current Assets has averaged $7.7 billion across 5 years, with a median of $7.6 billion in 2024.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets increased 16.18% in 2025, then declined 8.21% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $7.0 billion in 2022, then gained by 7.49% to $7.6 billion in 2023, then increased by 15.93% to $8.8 billion in 2024, then retreated by 2.72% to $8.5 billion in 2025, then fell by 5.3% to $8.1 billion in 2026.
- The last three Non-Current Assets figures came in at $8.1 billion (Q1 2026), $8.5 billion (Q4 2025), and $8.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 60.81 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 8.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.06 Bn |
| Dec 31, 2025 | 8.52 Bn |
| Sep 30, 2025 | 8.85 Bn |
| Jun 30, 2025 | 8.88 Bn |
| Mar 31, 2025 | 8.79 Bn |
| Dec 31, 2024 | 8.75 Bn |
| Sep 30, 2024 | 8.00 Bn |
| Jun 30, 2024 | 7.65 Bn |
| Mar 31, 2024 | 7.70 Bn |
| Dec 31, 2023 | 7.55 Bn |
| Sep 30, 2023 | 6.96 Bn |
| Jun 30, 2023 | 7.02 Bn |
| Mar 31, 2023 | 6.98 Bn |
| Dec 31, 2022 | 7.02 Bn |
| Sep 30, 2022 | 6.85 Bn |
| Jun 30, 2022 | 6.84 Bn |
| Mar 31, 2022 | 6.88 Bn |
| Dec 31, 2021 | 6.92 Bn |
| Sep 30, 2021 | 7.01 Bn |
| Jun 30, 2021 | 7.00 Bn |